2022 World Conference on Lung Cancer (ePosters)-EP08.02-038. Study of First-Line Aumolertinib Plus Bevacizumab and Pemetrexed Treated NSCLC with EGFR Mutation and Brain Metastasis

EP08.02-038. Study of First-Line Aumolertinib Plus Bevacizumab and Pemetrexed Treated NSCLC with EGFR Mutation and Brain Metastasis

Back to course

Pdf Summary

A recent study investigated the efficacy of combining aumolertinib, bevacizumab, and pemetrexed in the treatment of non-small cell lung cancer (NSCLC) patients with EGFR mutations and brain metastasis. The study aimed to explore the concept of a "chemo-weaken" strategy, which involved platinum-free single-drug chemotherapy combined with EGFR-tyrosine kinase inhibitors (TKIs) and bevacizumab. This strategy showed promising efficacy and a satisfactory safety profile.<br /><br />Previous studies have shown that EGFR-tyrosine kinase inhibitors, such as aumolertinib, can effectively treat NSCLC patients with brain metastasis. Additionally, the combination of EGFR-TKI and bevacizumab has demonstrated progression-free survival (PFS) benefits for patients with central nervous system (CNS) metastases. The aim of this study was to delay brain radiotherapy, potentially reducing long-term adverse effects.<br /><br />The primary endpoint of the study was PFS, while secondary endpoints included objective response rate (ORR) and safety. The study enrolled patients with EGFR mutations, no prior systemic anti-cancer/EGFR-TKI treatment, and confirmed brain metastases. The treatment regimen consisted of aumolertinib, bevacizumab, and pemetrexed for 4-6 cycles.<br /><br />The results showed promising efficacy, with an ORR of 80% and a disease control rate (DCR) of 100%. Intracranial ORR was 90% and intracranial DCR was 100%. The most common adverse event was a rash, and no grade 3-4 serious events occurred.<br /><br />In conclusion, the combination of aumolertinib, bevacizumab, and pemetrexed demonstrated superior activity and manageable toxicities in NSCLC patients with EGFR mutations and brain metastasis. The ongoing study will continue enrollment to determine longer-term outcomes, but the initial results provide a promising therapy strategy.

Asset Subtitle

Shuai Fu

Meta Tag

Speaker Shuai Fu

Topic Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

Keywords

aumolertinib

bevacizumab

pemetrexed

NSCLC

EGFR mutations

brain metastasis

chemo-weaken strategy

progression-free survival

central nervous system metastases

toxicities